Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00027 / http://dx.doi.org/10.20960/revcancer.00027

Resumen| PDF

Revisión

Tratamiento del cáncer de mama luminal tras inhibidores de ciclo celular

Rodrigo Sánchez Bayona, Manuel Alva Bianchi

Prepublicado: 2023-07-12

Publicado: 2023-07-12

VOLUMEN 37, NÚM. 1, enero-febrero (2023), PAG. 38-46

Logo Descargas Número de descargas: 16985 Logo Visitas Número de visitas: 1871 Citas Citas: 0

Compártelo:

La elección del tratamiento para aquellas pacientes que experimentan progresión tras inhibidores de CDK4/6 sigue siendo un desafío debido a la actividad subóptima o a las toxicidades significativas de las opciones actualmente disponibles. También hay pocos datos sobre la eficacia de combinaciones más antiguas, como everolimus + exemestano, tras inhibidores de CDK4/6. Ensayos clínicos recientes con nuevos fármacos han arrojado resultados prometedores en este contexto. No obstante, el estado de mutación de ESR1, PIK3CA y BRCA1/2 de la línea germinal son aspectos a tener en cuenta para las nuevas opciones disponibles (inhibidores de PI3K, nuevos SERD orales, inhibidores de PARP). Los nuevos anticuerpos conjugados (trastuzumab deruxtecán y sacituzumab govitecán) también han demostrado ser una opción eficaz de tratamiento en pacientes con cáncer de mama RH+/HER2-. En este artículo de revisión, resumimos la actividad de estas nuevas opciones de tratamiento y su papel potencial en futuros algoritmos de tratamiento.

Palabras Clave: SERD. PI3K. ESR1. Anticuerpos conjugados.

Descargar PDF

Bibliografía
Artículos Relacionados

Breast Cancer—Statistics [Internet]. Cancer.Net. 2012. Available online: https://www.cancer.net/cancer-types/breast-cancer/ statistics (accessed on 22 January 2023).

Slamon, D.J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Petrakova, K.; Valeria Bianchi, G.; Martín, M.; Nusch, A.; et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2021, 32, 1015–1024.

Jatoi, I.; Chen, B.E.; Anderson, W.F.; Rosenberg, P.S. Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis. J. Clin. Oncol. 2007, 25, 1683–1690.

Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015, 16, 25–35.

Finn, R.S.; Martin, M.; Rugo, H.S.; Jones, S.; Im, S.-A.; Gelmon, K.; Harbeck, N.; Lipatov, O.N.; Walshe, J.M.; Moulder, S.; et al. Palbociclib and Letrozole in Advanced Breast Cancer. N. Engl. J. Med. 2016, 375, 1925–1936.

Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.-S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K.L.; André, F.; Winer, E.P.; et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N. Engl. J. Med. 2016, 375, 1738–1748.

Goetz, M.P.; Toi, M.; Campone, M.; Sohn, J.; Paluch-Shimon, S.; Huober, J.; Park, I.H.; Trédan, O.; Chen, S.-C.; Manso, L.; et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 3638–3646.

Im, S.-A.; Lu, Y.-S.; Bardia, A.; Harbeck, N.; Colleoni, M.; Franke, F.; Chow, L.; Sohn, J.; Lee, K.-S.; Campos-Gomez, S.; et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N. Engl. J. Med. 2019, 381, 307–316.

Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Petrakova, K.; Blackwell, K.L.; Winer, E.P.; et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 2018, 29, 1541–1547.

Slamon, D.J.; Neven, P.; Chia, S.; Fasching, P.A.; De Laurentiis, M.; Im, S.-A.; Petrakova, K.; Bianchi, G.V.; Esteva, F.J.; Martín, M.; et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N. Engl. J. Med. 2020, 382, 514–524.

Bidard, F.-C.; Kaklamani, V.G.; Neven, P.; Streich, G.; Montero, A.J.; Forget, F.; Mouret-Reynier, M.-A.; Sohn, J.H.; Taylor, D.; Harnden, K.K.; et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J. Clin. Oncol. 2022, 40, 3246–3256.

Lindeman, G.J.; Fernando, T.M.; Bowen, R.; Jerzak, K.J.; Song, X.; Decker, T.; Boyle, F.; McCune, S.; Armstrong, A.; Shannon, C.; et al. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post- CDK4/6 Inhibitors—Efficacy, Safety, and Biomarker Results. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2022, 28, 3256–3267.

Kalinsky, K.; Accordino, M.K.; Chiuzan, C.; Mundi, P.S.; Trivedi, M.S.; Novik, Y.; Tiersten, A.; Raptis, G.; Baer, L.N.; Young Oh, S.; et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.J. Clin. Oncol. 2022, 40, LBA1004.

Cogliati, V.; Capici, S.; Pepe, F.F.; di Mauro, P.; Riva, F.; Cicchiello, F.; Maggioni, C.; Cordani, N.; Cerrito, M.G.; Cazzaniga, M.E. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life 2022, 12, 378.
DOI: 10.3390/life12030378

McCartney, A.; Migliaccio, I.; Bonechi, M.; Biagioni, C.; Romagnoli, D.; De Luca, F.; Galardi, F.; Risi, E.; De Santo, I.; Benelli, M.; et al. Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front. Oncol. 2019, 9, 666.

Robertson, J.F.R.; Bondarenko, I.M.; Trishkina, E.; Dvorkin, M.; Panasci, L.; Manikhas, A.; Shparyk, Y.; Cardona-Huerta, S.; Cheung, K.-L.; Philco-Salas, M.J.; et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial. Lancet 2016, 388, 2997–3005.

Chia, S.; Gradishar, W.; Mauriac, L.; Bines, J.; Amant, F.; Federico, M.; Fein, L.; Romieu, G.; Buzdar, A.; Robertson, J.F.R.; et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26, 1664–1670.

Di Leo, A.; Jerusalem, G.; Petruzelka, L.; Torres, R.; Bondarenko, I.N.; Khasanov, R.; Verhoeven, D.; Pedrini, J.L.; Smirnova, I.; Lichinitser, M.R.; et al. Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J. Natl. Cancer Inst. 2014, 106, djt337.

Garcia-Fructuoso, I.; Gomez-Bravo, R.; Schettini, F. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. Curr. Opin. Oncol. 2022, 34, 635
DOI: 10.1097/CCO.0000000000000892

Fribbens, C.; O’Leary, B.; Kilburn, L.; Hrebien, S.; Garcia-Murillas, I.; Beaney, M.; Cristofanilli, M.; Andre, F.; Loi, S.; Loibl, S.; et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016, 34, 2961–2968.
DOI: 10.1200/JCO.2016.67.3061

Turner, N.C.; Kingston, B.; Kilburn, L.S.; Kernaghan, S.; Wardley, A.M.; Macpherson, I.R.; Baird, R.D.; Roylance, R.; Stephens, P.; Oikonomidou, O.; et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): A multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020, 21, 1296–1308.

SABCS 2022 [Internet]. Disponible online: https://www.eventscribe.net/2022/SABCS/fsPopup.asp?PresentationID=1156609& query=SERENA&Mode=presInfo (accedido en marzo 2023).

AstraZeneca. A Phase III, Double-Blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients with Detectable ESR1Mutation without Disease Progression during 1L Treatment with Aromatase Inhibitor+ CDK4/6 Inhibitor–A ctDNA Guided Early Switch Study [Internet]. clinicaltrials.gov; Report No.: NCT04964934. 2022. Disponible online: https://clinicaltrials.gov/ct2/show/NCT04964934.

Bidard, F.C.; Hardy-Bessard, A.C.; Dalenc, F.; Bachelot, T.; Pierga, J.Y.; de la Motte Rouge, T.; Sabatier, R.; Dubot, C.; Frenel, J.S.; Ferrero, J.M.; et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022, 23, 1367–1377.

Jhaveri, K.L.; Lim, E.; Hamilton, E.P.; Saura, C.; Meniawy, T.; Jeselsohn, R.; Beck, J.T.; Kaufman, P.A.; Sammons, S.; Banda, K.; et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. J. Clin. Oncol. 2021, 39, 1050.

Eli Lilly and Company. EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy [Internet]. clinicaltrials.gov; Report No.: NCT04975308. 2023. Available online: https://clinicaltrials.gov/ct2/show/NCT04975308 (accessed on 26 January 2023).

Xie, H.; Liu, J.; Alem Glison, D.M.; Fleming, J.B. The clinical advances of proteolysis targeting chimeras in oncology. Explor. Target. Anti-Tumor Ther. 2021, 2, 511–521.

Hanker, A.B.; Sudhan, D.R.; Arteaga, C.L. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell 2020, 37, 496–513.

ARV-471 Monotherapy Demonstrates Clinical Benefit in ER+/HER2-Advanced Breast Cancer [Internet]. OncLive. Available online: https://www.onclive.com/view/arv-471-monotherapy-demonstrates-clinical-benefit-in-er-her2--advanced-breast- cancer (acceso en enero 2023).

Pfizer. A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer Whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2) [Internet]. clinicaltrials.gov; Report No.: NCT05654623. 2022. Available online: https://clinicaltrials.gov/ct2/show/NCT05654623 (acceso en enero 2023).

Bachman,K.E.;Argani,P.;Samuels,Y.;Silliman,N.;Ptak,J.;Szabo,S.;Konishi,H.;Karakas,B.;Blair,B.G.;Lin,C.;etal.The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3, 772–775.

Miron, A.; Varadi, M.; Carrasco, D.; Li, H.; Luongo, L.; Kim, H.J.; Park, S.Y.; Cho, E.Y.; Lewis, G.; Kehoe, S.; et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010, 70, 5674–5678.

Kodahl,A.R.;Ehmsen,S.;Pallisgaard,N.;Jylling,A.M.B.;Jensen,J.D.;Laenkholm,A.-V.;Knoop,A.S.;Ditzel,H.J.Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol. Oncol. 2018, 12, 925–935.

Dumbrava,E.E.;Call,S.G.;Huang,H.J.;Stuckett,A.L.;Madwani,K.;Adat,A.;Hong,D.S.;Piha-Paul,S.A.;Subbiah,V.;Karp, D.D.; et al. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 2021, 6, 100230.
DOI: 10.1016/j.esmoop.2021.100230

Criscitiello,C.;Viale,G.;Curigliano,G.;Goldhirsch,A.Profileofbuparlisibanditspotentialinthetreatmentofbreastcancer: Evidence to date. Breast Cancer 2018, 10, 23–29.

André, F.; Ciruelos, E.M.; Juric, D.; Loibl, S.; Campone, M.; Mayer, I.A.; Rubovszky, G.; Yamashita, T.; Kaufman, B.; Lu, Y.-S.; et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: Final overall survival results from SOLAR-1. Ann. Oncol. 2021, 32, 208–217.

Rugo,H.S.;Lerebours,F.;Ciruelos,E.;Drullinsky,P.;Ruiz-Borrego,M.;Neven,P.;Park,Y.H.;Prat,A.;Bachelot,T.;Juric,D.; et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021, 22, 489–498.

Juric,D.;Rugo,H.S.;Chia,S.K.L.;Lerebours,F.;Ruiz-Borrego,M.;Drullinsky,P.;Ciruelos,E.M.;Neven,P.;Park,Y.H.;Arce, C.H.; et al. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. J. Clin. Oncol. 2022, 40, 1018.

PI3KΑInhibitorMoleculeOverview|LoxoOncology[Internet].Availableonline:https://www.lillyloxooncologypipeline. com/molecule/pi3k-alpha-inhibitor (acceso febrero 2023).

RelayTherapeutics,Inc.AFirst-in-HumanStudyofMutant-SelectivePI3KαInhibitor,RLY-2608,asaSingleAgentinAdvanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer [Internet]. clinicaltrials.gov; Report No.: NCT05216432. 2022. Available online: https://clinicaltrials.gov/ct2/show/NCT05216432 (acceso febrero 2023).

Howell,S.J.;Casbard,A.;Carucci,M.;Ingarfield,K.;Butler,R.;Morgan,S.;Meissner,M.;Bale,C.;Bezecny,P.;Moon,S.;etal. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): Overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022, 23, 851–864.

AstraZeneca.APhaseIb/IIIRandomisedStudyofCapivasertibPlusPalbociclibandFulvestrantVersusPlaceboPlusPalbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer [Internet]. clinicaltrials.gov; Report No.: NCT04862663. 2022. Available online: https://clinicaltrials.gov/ct2/show/NCT04862663 (acceso febrero 2023).

Templeton,A.J.;Ace,O.;Amir,E.;Vera-Badillo,F.;Ocana,A.;Pond,G.R.;Tannock,I.F.Influenceofcensoringonconclusionsof trials for women with metastatic breast cancer. Eur. J. Cancer 2015, 51, 721–724.

Piccart,M.;Hortobagyi,G.N.;Campone,M.;Pritchard,K.I.;Lebrun,F.;Ito,Y.;Noguchi,S.;Perez,A.;Rugo,H.S.;Deleu,I.;etal. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2014, 25, 2357–2362.

Robson,M.E.;Tung,N.;Conte,P.;Im,S.-A.;Senkus,E.;Xu,B.;Masuda,N.;Delaloge,S.;Li,W.;Armstrong,A.;etal.OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019, 30, 558–566.

Litton,J.K.;Hurvitz,S.A.;Mina,L.A.;Rugo,H.S.;Lee,K.-H.;Gonçalves,A.;Diab,S.;Woodward,N.;Goodwin,A.;Yerushalmi, R.; et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: Final overall survival results from the EMBRACA trial. Ann. Oncol. 2020, 31, 1526–1535.

Continuing CDK4/6 Inhibitor beyond Progression No Help in Metastatic Breast Cancer [Internet]. 2022. Available online: https://www.medpagetoday.com/meetingcoverage/sabcs/102159 (acceso enero 2023).

Pfizer. PHASE 1/2A Dose Escalation and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Anti-Tumor Activity of PF-06873600 as a Single Agent and in Combination with Endocrine Therapy [Internet]. clinicaltri- als.gov; Report No.: NCT03519178. 2022. Available online: https://clinicaltrials.gov/ct2/show/NCT03519178 (acceso enero 2023).

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine. July 7, 2022;387(1):9–20.

Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. June 10, 2020;38(17):1951–1962.

AstraZeneca. A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) [Internet]. clinicaltrials.gov 2022 Jul [cited July 27, 2022]. Report No.: NCT04494425. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04494425

Vidula N, Yau C, Rugo HS. Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics. JCO. May 20, 2017;35(15_suppl):1075–1075.
DOI: 10.1200/JCO.2017.35.15_suppl.1075

Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O’Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. December 2020;31(12):1709–1718.

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. JCO. June 10, 2022;40(17_suppl):LBA1001–LBA1001.
DOI: 10.1200/JCO.2022.40.17_suppl.LBA1001

Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). JCO. June 1, 2022;40(16_suppl):1002– 1002.
DOI: 10.1200/JCO.2022.40.16_suppl.1002

SOLTI Breast Cancer Research Group. A Window-of-opportunity Study of U3-1402, a HER3- targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression [Internet]. clinicaltrials.gov 2021 Jan [cited April 14, 2021]. Report No.: NCT04610528. Available at: https://clinicaltrials.gov/ct2/show/NCT04610528